| Parameter | Results |
| Age at SRC diagnosis, years (mean (SD)) | 53.3 (14.5) |
| Gender (female/male) | 37/13 |
| SSc duration, months (mean (SD)) | 27.7 (49.1) (median: 7.8) |
| RP, n (%) | 41/49 (91.8) |
| Duration of RP, mo (mean (SD)) | 68.3 (133.7) (median: 20.3) |
| Type of SSc | |
| Diffuse cutaneous, n (%) | 43 (86) |
| Limited cutaneous, n (%) | 5 (10) |
| Limited, n (%) | 2 (4) |
| Organ involvement | |
| Interstitial lung disease, n (%) | 32/35 (91.4) |
| Interstitial lung disease with restrictive syndrome, n (%) | 27/47 (57.4) |
| Pulmonary arterial hypertension, n (%) | 2 (4) |
| Left ventricular insufficiency, n (%) | 23 (46) |
| Gastro-intestinal, n (%) | 42 (84) |
| Oesophagus, n (%) | 39 (78) |
| Bowel, n (%) | 8 (16) |
| Other | |
| Arthralgia, n (%) | 43 (86) |
| Arthritis, n (%) | 7 (14) |
| Myalgias, n (%) | 15 (30) |
| Myopathy, n (%) | 4 (8) |
| Oedema, n (%) | 30 (60) |
| Immunological tests | |
| Anti-nuclear Abs | 45 (90) |
| Anti-topoisomerase 1 Abs | 14 (32)* |
| Anti-centromere Abs | 0 |
*Values missing for 6 individuals.
Abs, antibodies; RP, Raynaud phenomenon; SRC, scleroderma renal crisis; SSc, systemic sclerosis.